Key result
TNF-α inhibition with etanercept significantly reduced urinary protein excretion (514 vs 703 mg/day; P<0.05) and renal inflammation markers in DOCA-salt hypertensive rats without affecting blood pressure.
Why the study?
Does etanercept reduce renal injury and inflammation in DOCA-salt hypertensive rats?
Population
Rats in a model of mineralocorticoid-induced hypertension (DOCA-salt), 4 groups of n=5 or 6
Comparison
TNF-α inhibitor etanercept added to DOCA-salt vs DOCA-salt alone, placebo alone, and placebo +…
Design
Preclinical
Follow-up
3 weeks
Authors
Loading...
Hypothesis-generating for TNF-α blockade in hypertensive nephropathy; extends evidence for BP-independent renal protection in mineralocorticoid models.
Does etanercept reduce renal injury and inflammation in DOCA-salt hypertensive rats?
Absolute Event Rate: 514% vs 703%
p-value: p=<0.05
TNF-α inhibition with etanercept reduces renal inflammation and injury in mineralocorticoid-induced hypertension independent of blood pressure lowering.
Elmarakby et al. (2007) studied DOCA-salt hypertension. Etanercept (TNF-α inhibitor) vs. Placebo or DOCA-salt alone was evaluated on Urinary protein excretion (p=<0.05). TNF-α inhibition with etanercept significantly reduced urinary protein excretion (514 vs 703 mg/day; P<0.05) and renal inflammation markers in DOCA-salt hypertensive rats without affecting blood pressure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: